Table 3.
Ongoing Clinical Trials of Novel Treatment Approaches in FLT3 Positive AML
| Therapeutic Approach | Patient Group | Phase | Clinical Trial Number |
|---|---|---|---|
| Azacitidine plus Venetoclax (BCL-2 inhibitor) | Previously untreated AML patients who are unsuitable for treatment | Phase III | NCT02993523 |
| S64315 (MCL-1 inhibitor) + Venetoclax | Relapsed or refractory AML patients | Phase I | NCT03672695 |
| VOB560 (BCL-2 inhibitor) + MIK665 (MCL-1 inhibitor) | Relapsed or refractory patients with NHL, MM and AML | Phase I | NCT04702425 |
| FF-10101-01 (novel FLT3i) | Patients with refractory or relapsed AML and who are not eligible for any treatment | Phase I/II | NCT03194685 |
| HM43239 (novel FLT3i) | Refractory or relapsed AML patients | Phase I/II | NCT03850574 |
| SEL24/MEN1703 (Dual FLT3/PIM kinase inhibitor) | Refractory or relapsed AML patients who cannot receive any approved treatment | Phase I/II | NCT03008187 |
| CG-806 (Luxeptinib) (Dual FLT3/BTK kinase inhibitor) | Patients with refractory or relapsed AML or high risk MDS and intolerant of chemotherapy or transplantation | Phase I | NCT04477291 |
| MAX-40279-01 (FGFR/FLT3 dual inhibitor) | Relapsed or refractory AML patients | Phase I | NCT04187495 |
| Ibrutinib (BTK inhibitor) with chemotherapy in the absence or presence of an FLT3i | Relapsed or refractory AML patients with FLT3 mutation | Phase II/III | NCT03642236 |
| IMC-EB10 (anti-FLT3 antibody) | Relapsed or refractory AML patients | Phase I | NCT00887926 |
| FLYSYN (Fc-optimized FLT3 antibody) | AML patients with minimal residual disease | Phase I/II | NCT02789254 |
| AMG 553 (FLT3 CAR-T) | Relapsed or refractory AML patients with FLT3 mutation | Phase I | NCT03904069 |
Abbreviations: NHL, non-Hodgkin lymphoma; MM, multiple myeloma; MDS, myelodysplastic syndrome.